Capricor publishes new advances for its engineered exosome platform

Capricor Announces Publication Highlighting New Advances for its ...

StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan.

Capricor Therapeutics to Present Exosome Platform Updates at ...

Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused ...

Capricor Announces Publication Highlighting New Advances

StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan.

Capricor Announces Peer-Reviewed Publication Demonstrating the ...

Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's focus is on developing exosomes ...

Capricor Therapeutics to Present Exosome Platform Updates at the ...

Capricor is also harnessing the power of our exosome technology, using our proprietary StealthX™ platform in preclinical development focused ...

Capricor Therapeutics Announces Collaboration with the National ...

“We are extremely pleased with the external support from the NIH, which highlights the clinical potential of our StealthX™ exosome platform ...

Capricor Therapeutics Announces Publication Demonstrating ...

The ability to manipulate cells provides read through to our exosome product candidates which are being engineered to treat specific diseases.

capricor | Exosome RNA

Capricor publishes new advances for its engineered exosome platform ... StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to ...

Capricor Therapeutics Announces Publication Demonstrating ...

What recent publication did Capricor Therapeutics release regarding its exosome platform? ... Capricor published a study demonstrating enhanced ...

Untitled

... Capricor to continue the expansion of our engineered exosome platform technology,” said Linda Marbán, Ph.D., CEO, Capricor Therapeutics. In parallel, we ...

Capricor Therapeutics Signs Exclusive Worldwide ... - Exosome RNA

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology ...

Capricor licenses exosome platform tech from Johns Hopkins

April 30, 2021 -- Biotech company Capricor Therapeutics announced it has signed an exclusive worldwide licensing agreement with Johns Hopkins University to ...

Capricor Therapeutics Announces Strategic Plan for Exosome ...

More specifically, Capricor has utilized this technology in pre-clinical studies of inflammation and intense immune activation such as DMD, ...

New advances in exosome-based targeted drug delivery systems

Exosomes therapeutic potential can be greatly enhanced by engineering their content. •. Multiple exosome surface engineering strategies have been developed. •.

Capricor Therapeutics Announces Strategic Plan for Exosome

While Capricor's CDC-derived exosomes have strong clinical potential, Capricor is committed to developing precision-engineered exosomes that ...

Capricor Therapeutics Announces Publication Demonstrating ...

Linda Marbán, Ph.D., CEO of Capricor. “This data was the foundation of our new platform, which has allowed us to expand our reach to engineering ...

Capricor Therapeutics to Update on Exosome Platform at ASGCT ...

Capricor Therapeutics, a biotech firm at the forefront of cell and exosome-based treatments for rare diseases, has announced a significant ...

Press Release, titled “Capricor Therapeutics Reports First Quarter ...

Additionally, we continue to make progress with our engineered exosomes platform as we have invested internally in developing a scaled-up ...

The emerging role of exosomes as novel therapeutics: Biology ...

The company has unique patented technology which allows active loading of large size proteins into luminal side of exosomes. With its current lead therapeutic ...

Capricor Therapeutics Announces Development of Serology Test to ...

“Capricor's dedication to developing its exosome-based RNA delivery platform is enhanced by the invention, development and access to new, ...